ライフサイエンスコーパス: graft rejection

1 primary endpoint 'time to first endothelial graft rejection'.

2 se models of inflammatory arthritis and lung-graft rejection.

3 associated with an increased rate of corneal graft rejection.

4 in cases of bowel dysfunction not related to graft rejection.

5 s cross-react with allogeneic Ag and mediate graft rejection.

6 nd triggers BKPyV-associated nephropathy and graft rejection.

7 ransplantation remains profoundly limited by graft rejection.

8 erative management and prevention of corneal graft rejection.

9 cell-specific IL-10 deficient mice prevented graft rejection.

10 cardiac allograft specimens undergoing acute graft rejection.

11 A at this time significantly reduced corneal graft rejection.

12 initiation of adaptive responses that cause graft rejection.

13 between groups were observed in the risk of graft rejection.

14 by the immunosuppression required to prevent graft rejection.

15 s a key event in triggering alloimmunity and graft rejection.

16 y cross-react with allogeneic Ags to mediate graft rejection.

17 engraftment and more efficacy in controlling graft rejection.

18 ith fewer deaths resulting from GvHD or from graft rejection.

19 ferentiation after transplantation and rapid graft rejection.

20 logeneic non-self by monocytes in initiating graft rejection.

21 en associated with more risk for solid organ graft rejection.

22 mmunosuppression significantly reduced early graft rejection.

23 osuppressive treatment to prevent allogeneic graft rejection.

24 nomodulatory activity and its implication on graft rejection.

25 ications for the prevention and treatment of graft rejection.

26 ute to risk for opportunistic infections and graft rejection.

27 fers advantages in the form of lower risk of graft rejection.

28 led to induce tolerance but also accelerated graft rejection.

29 for the treatment of autoimmune diseases and graft rejection.

30 ltration of effector T cells, and ultimately graft rejection.

31 elopment of immunotherapies to prevent islet graft rejection.

32 usly other reasons than just pure allogeneic graft rejection.

33 trated to be markedly upregulated in corneal graft rejection.

34 bsequent procedures were not associated with graft rejection.

35 prognostic role of 3D En/DMT maps in corneal graft rejection.

36 the CD8+ T effector cells requisite for skin graft rejection.

37 We identified 45 cases of graft rejection.

38 o decades to reverse steroid-resistant acute graft rejection.

39 ell as in preventing autoimmune diseases and graft rejection.

40 may be useful for the treatment of vascular graft rejection.

41 per of T cell lineage development in cardiac graft rejection.

42 lation of MDSC can participate in preventing graft rejection.

43 ata, lifelong immunosuppression, and chronic graft rejection.

44 low the clinical and immunologic outcomes of graft rejection.

45 ter established tolerance resulted in prompt graft rejection.

46 ut also alloantibody elaboration and chronic graft rejection.

47 y between alloimmunity and autoreactivity in graft rejection.

48 of transplantation abrogates protection from graft rejection.

49 ining and validating an imaging signature of graft rejection.

50 diators and accelerate T cell-meditated skin graft rejection.

51 n this study, irrespective of interval acute graft rejection.

52 ve therapeutic potential for T cell-mediated graft rejection.

53 ients' hypoparathyroidism due to parathyroid graft rejection.

54 ould be kept in mind as a rare sign of DSAEK graft rejection.

55 immune responses in autoimmune diseases and graft rejection.

56 l response in vivo and the perceived risk of graft rejection.

57 fic antibody responses and accelerated heart graft rejection.

58 ressive therapy, which increases the risk of graft rejection.

59 formation, suture-related complications, and graft rejection.

60 ed to clinical signs and symptoms of corneal graft rejection.

61 ce of clinical signs and symptoms of corneal graft rejection.

62 potential contributors to antibody-mediated graft rejection.

63 renal transplant recipients and can lead to graft rejection.

64 help further combat autoimmune diseases and graft rejection.

65 ll as during chronic antibody-mediated heart graft rejection.

66 l in the diagnosis and management of corneal graft rejection.

67 daptive immunity may contribute and modulate graft rejection.

68 in hopes of reducing relapse and decreasing graft rejection.

69 esis has been successfully used to attenuate graft rejection.

70 pressive medications administered to prevent graft rejection.

71 ression and restricted T cell activation and graft rejection.

72 g therapy for T1D has been hampered by early graft rejection.

73 vation, differentiation, and the kinetics of graft rejection.

74 En/DM) characteristics in diagnosing corneal graft rejection.

75 allografts, and enable better prediction of graft rejection.

76 cell transplantation to reduce immunological graft rejection.

77 drawal should be selected carefully to avoid graft rejection.

78 desensitization, and assessing the risk for graft rejection.

79 apeutic approaches to autoimmune diseases or graft rejections.

80 yte autoantibodies are associated with fewer graft rejections.

81 3 years after DSAEK and PKP were immunologic graft rejection (0.6% vs. 3.1%), endothelial decompensat

82 A 58-year-old female presented with graft rejection 1 year following a DSAEK procedure.

83 ons in these patients included glaucoma (1), graft rejection (1), recurrence of disease (1), and ambl

84 The complications noted in the patients were graft rejection (1), shield ulcers (2), graft infection

85 s that underwent DMEK had the lowest rate of graft rejection (1.7% vs DSAEK 5.0% vs PK 14.1%, P < .00

86 netrating keratoplasty (15 eyes with corneal graft rejection, 23 eyes without rejection) and 9 age-ma

87 Thirty of 353 DSAEKs developed graft rejection (8.5%).

88 ine, or DSP in solution demonstrated corneal graft rejection accompanied by severe corneal edema, neo

89 erum creatinine concentrations and to kidney graft rejection after about a month.

90 Graft rejection after cryptococcosis was observed in 15.

91 at a physiological ratio were able to delay graft rejection after direct alloreactivity by controlli

92 The risk for graft rejection after DMEK is low, and an even smaller m

93 e of ECD loss with time in eyes experiencing graft rejection after DSAEK surgery.

94 onstellation also predicted the incidence of graft rejection after liver and lung transplantation, wi

95 atment of autoimmune diseases and to prevent graft rejection after organ transplantation.

96 ular pathologies constitute a major cause of graft rejection after organ transplantation.

97 enesis and lymphangiogenesis, and suppressed graft rejection after transplantation.

98 mem) can play an important role in mediating graft rejection after transplantation.

99 ls of immunosuppression, balancing risks for graft rejection against risks for infection.

100 et-expressed antigens is prevented and islet graft rejection alleviated.

101 genes would explain why cheetahs ablate skin graft rejection among unrelated individuals.

102 is evidence that NK cells can contribute to graft rejection and also to tolerance induction.

103 ished models of acute and chronic intestinal graft rejection and analyzed peripheral and intragraft i

104 recipient age, African American race, acute graft rejection and CMV infection were significantly ass

105 number of TIM-3+ Tregs peaked at the time of graft rejection and declined thereafter.

106 cell accumulation, resulting in accelerated graft rejection and decreased tumor volume in mouse mode

107 tigenic targets that have been implicated in graft rejection and discuss the interplay between alloim

108 DMEK also had a significantly lower rate of graft rejection and elevated intraocular pressure compar

109 t-operative complications and lower rates of graft rejection and failure.

110 g H-Y incompatibility, on corneal transplant graft rejection and failure.

111 nt seroconstellation remains associated with graft rejection and graft loss in the era of prophylacti

112 sphamide after transplantation inhibits both graft rejection and graft-versus-host disease (GvHD) in

113 apa cells skewed toward a Th2-type prevented graft rejection and graft-versus-host disease (GVHD) mor

114 -transplantation cyclophosphamide to prevent graft rejection and graft-versus-host disease (GVHD).

115 in from day -5 to -3 was used for preventing graft rejection and graft-versus-host disease (GVHD); no

116 egrees of preparative regimen intensity, but graft rejection and graft-vs-host disease remain signifi

117 se studies suggest that ICOS plays a role in graft rejection and GVHD in an outbred animal model, and

118 Anti-E-selectin treatment delayed graft rejection and increased survival compared with con

119 on; one died at 183 days as a consequence of graft rejection and infection.

120 teroid avoidance appears safe with regard to graft rejection and loss in pediatric kidney transplant

121 H60 incompatibility does not result in skin graft rejection and only a minority of heart transplants

122 ng infection, cancer, autoimmunity, allergy, graft rejection and other immunological processes.

123 T(reg) cells leads to autoimmune disease and graft rejection and promotes anti-tumor immunity.

124 As T cells play a key role in both undesired graft rejection and protection, a better understanding o

125 Graft rejection and rebubbling rates were similar in DME

126 tivation (including opportunistic infection, graft rejection and severe hepatitis C virus recurrence)

127 ations of bone marrow transplants, including graft rejection and the chronic immunosuppression requir

128 ) regulatory T cells (nTregs) in controlling graft rejection and the mechanism used remain controvers

129 ithin the hematopoietic compartment leads to graft rejection and therapeutic failure because of antig

130 sed at a physiological ratio failed to delay graft rejection and to control proliferation of conventi

131 Investigations in diverse areas, including graft rejection and tolerance, autoimmunity and infectio

132 lassemia is challenging due to high rates of graft rejection and transplant-related mortality.

133 in addition to T cells, B cells can mediate graft rejection and transplantation tolerance.

134 f CCL22 could be harnessed for prevention of graft rejection and type 1 diabetes as well as other aut

135 tients, particularly modifiable factors like graft rejection and urinary tract infection.

136 tal tool for timely prevention of intestinal graft rejection and, more important, avoidance of overim

137 e, the result may be a situation that favors graft rejection and/or makes tolerance difficult to achi

138 or source of pathogenic Abs in autoimmunity, graft rejection, and allergy.

139 ization, cellular and molecular mediators of graft rejection, and allotolerance induction.

140 ma includes withdrawal of immunosuppression, graft rejection, and explantation of the allograft after

141 on of rare SNPs in malignancy, monitoring of graft rejection, and fetal screening.

142 substantial risk for de novo DSA formation, graft rejection, and graft failure after kidney transpla

143 We correlated CMV infection, biopsy-proven graft rejection, and graft loss in 1,414 patients receiv

144 arization, need for transplantation, risk of graft rejection, and QoL.

145 common opportunistic viral infections and of graft rejection, and should facilitate point-of-care pos

146 s are nonspecific and occur in pancreatitis, graft rejection, and subsequent graft ischemia.

147 strike implies a central role for B cells in graft rejection, and this approach may help to delay or

148 critically involved in tissue fluid balance, graft rejection, and tumor metastasis.

149 However, concerns about relapse, graft rejection, and variability in technique have limit

150 munosuppression, which increases the risk of graft rejection, anti-CD20 treatment, combination chemot

151 Rates of graft rejection are high among recipients of heart trans

152 ive thickening of the En/DM is diagnostic of graft rejection as measured by DMT and DRI.

153 tegy and could be used both to prevent acute graft rejection as well as for maintenance immunosuppres

154 exacerbated ischemia/reperfusion injury and graft rejection, as demonstrated by increased myocardial

155 r anti-CD200R1/R2 monoclonal antibody caused graft rejection, as did anti-interleukin (IL)-9, anti-IL

156 veloped hemophagocytic syndrome, followed by graft rejection at day +17.

157 ning the biological pathways responsible for graft rejection at the molecular level and identifying g

158 we found a trend toward a lower incidence of graft rejection at year 1 in the "monitoring" group (30.

159 as well as CXCL9 messenger RNA (a marker of graft rejection) at elevated levels in urine samples fro

160 e any impact on complications such as death, graft rejection, bacterial or CMV infections.

161 Most early PTLD patients experienced graft rejection before PTLD diagnosis (P=0.0081).

162 Incidence of graft rejection, best spectacle-corrected visual acuity

163 d no differences in incidence or severity of graft rejection between groups.

164 osporine, markedly attenuated not only acute graft rejection but also alloantibody elaboration and ch

165 Immunosuppression prevents graft rejection but seems to accelerate the recurrence o

166 s found that T cells play a critical role in graft rejection, but can also be major players in mediat

167 odies (DSA) are associated with acute kidney graft rejection, but their role in small bowel/multivisc

168 autoimmune diseases, allergic disorders, and graft rejection by depleting undesired disease-causing T

169 y (IVCM) can aid in the diagnosis of corneal graft rejection by detecting cellular corneal changes th

170 Assessment of patients with corneal graft rejection by IVCM may serve as an adjunctive tool

171 CNI reduction and elimination, and risk for graft rejection; (C) antiproliferative effects of EVR; a

172 However, graft rejection can occur long after a state of transpla

173 ly demanding processes such as autoimmunity, graft rejection, cancer and uncontrolled inflammation co

174 g risk factors traditionally associated with graft rejection, cessation of topical steroids was most

175 posttransplant mortality, graft loss, acute graft rejection, chronic rejection, cancer, infection, a

176 during the first year posttransplant (acute graft rejection, chronically elevated anxiety, less time

177 Outcome measures included rates of graft rejection, clinical findings, treatment outcomes,

178 receiving intensified immunosuppression for graft rejection, CMV infection, higher dose of corticost

179 pecific Tregs offers greater protection from graft rejection compared to polyclonal Tregs.

180 nhibition or even acceleration of donor skin graft rejection compared with non-DST control (naive) bm

181 effects on hemodynamically significant/fatal graft rejection, coronary vasculopathy, terminal cancer,

182 t prominent, suggesting that T cell-mediated graft rejection could be the cause of the late-phase isl

183 Patients with corneal graft rejection demonstrate a significant increase in co

184 ourse of autoimmune, infectious, and chronic graft rejection diseases, in which a sustained lymphocyt

185 dney graft function, TrBs from patients with graft rejection displayed similar IL-10 expression level

186 btly yet reproducibly decreases time to skin graft rejection elicited by central but not effector mem

187 A graft rejection episode developed in 12 patients (estima

188 Eyes with a graft rejection episode had a higher median percentage d

189 Patients with a graft rejection episode were followed up for 1 additiona

190 analyze the incidence and clinical course of graft rejection episodes after Descemet membrane endothe

191 Patients with graft rejection episodes and late endothelial failure we

192 (<1%) cumulative probability of immunologic graft rejection episodes through 2 years after DMEK.

193 Graft rejection episodes were seen in 5 eyes (12.1%) in

194 splant recipients is a major risk factor for graft rejection episodes, and it has significant financi

195 t all time points compared with eyes without graft rejection episodes.

196 elease of corticosteroids to prevent corneal graft rejection following subconjunctival injection prov

197 ho are medically immunosuppressed to prevent graft rejection, have increased melanoma risk, but risk

198 mune disease, inflammatory bowel disease and graft rejection, however the mechanisms by which they ca

199 In a setting of CD8(+) cell-dominant graft rejection, IL-6 neutralization delayed the onset o

200 trophils, were confirmed by third-party skin graft rejection; importantly, a graft-versus-leukemia as

201 at had rejected corneal allografts, produced graft rejection in 70% and 20% of the hosts, respectivel

202 d gene transfer of thymosin beta4 attenuated graft rejection in a heterotopic heart transplantation m

203 er Th2 cells alone accounted for accelerated graft rejection in allergic mice.

204 ction by alloprimed IgG1 B cells and delayed graft rejection in both low and high alloantibody produc

205 has been associated with atherosclerosis and graft rejection in heart transplant recipients.

206 arrier function, homeostatic regulation, and graft rejection in intestinal transplantation (ITx) pati

207 Importantly, blockade of TNFR2 attenuated graft rejection in low- but not high-affinity-primed ani

208 were performed to determine risk factors for graft rejection in LR HLAid recipients.

209 to directly alloreactive T cells and delayed graft rejection in mice.

210 hibitor Rapamycin, could significantly delay graft rejection in one mouse strain, and achieve transpl

211 While CsA has been widely used to prevent graft rejection in patients undergoing organ transplant

212 tigated the putative candidate biomarkers of graft rejection in peripheral blood of intestinal transp

213 We further demonstrate that late graft rejection in recipients treated with this regimen

214 HLA mismatching is a risk factor for graft rejection in solid organ transplantation.

215 s to develop a pre-clinical model of corneal graft rejection in the semi-inbred NIH minipig as a mode

216 In this study, we examined graft rejection in three mouse models: 1) mismatch of ma

217 of microchimerism in predicting the risk of graft rejection in transplantation.

218 vitro Ag-specific Foxp3(+) nTregs to control graft rejection in transplantation.

219 f pTregs from mice at low risk of subsequent graft rejection is able to rescue graft survival in reci

220 Graft rejection is an important complication following D

221 Diagnosis of graft rejection is based on patient symptoms and on clin

222 hus, allergy-induced exacerbation of corneal graft rejection is due to the production of IL-4, which

223 RESULT: CD4 T cell-mediated cardiac graft rejection is inhibited using RIP3 deficient donor

224 Immunologic graft rejection is one of the main causes of short and l

225 nocytes and macrophages contribute to kidney graft rejection is poorly understood.

226 Allogeneic graft rejection is shown to follow a 4-stage clinical pr

227 responses in vivo, as demonstrated by faster graft rejection kinetics and greater proliferative respo

228 -modified DCs prior to transplantation, skin graft rejection kinetics were similar to those in non-DC

229 In this study, we examined the graft-rejection kinetics and CD4(+) and CD8(+) donor-rea

230 One graft rejection leading to graft failure was seen and wa

231 There were no differences in rates of graft rejection, leukemia relapse, treatment-related mor

232 A graft rejection-like program occurs in the ZAM, which in

233 n with associated complications, and chronic graft rejection, limit its wide clinical application.

234 the required frequency of dosing for corneal graft rejection management can be as high as once every

235 ated to ischemia-reperfusion injury (IRI) or graft rejection may be silenced to improve organ quality

236 transplantation in patients, irrespective of graft rejection, may be high at the time of humoral reje

237 upregulated on memory T cells, did not delay graft rejection mediated by CXCR3 memory T cells.

238 patients can develop an accelerated form of graft rejection mediated by humoral and T-cell-mediated

239 ntidonor T cell priming in a MyD88-dependent graft rejection model.

240 The increased graft rejection observed in conventional animals was due

241 estricted to a single foreign antigen on the graft, rejection occurred only if the allogeneic non-sel

242 otypic differences are capable of triggering graft rejection of an organ transplanted between identic

243 There was one episode of graft rejection on belatacept therapy in a patient who h

244 need to better understand the mechanisms of graft rejection or acceptance.

245 y up-regulated on T cells in dogs undergoing graft rejection or chronic GVHD after allogeneic hematop

246 is multifactorial and can be an indicator of graft rejection or coronary artery vasculopathy.

247 Main outcome measures were graft rejection or failure at 5 years.

248 by T cell-mediated alloresponses that cause graft rejection or graft-versus-host disease.

249 ty and as such could serve as biomarkers for graft rejection or tolerance.

250 e (OR = 2.67; 95% CI = 1.12-6.32), and acute graft rejection (OR = 3.01; 95% CI = 1.78-5.09).

251 6; 95% CI: 1.04-339.37; p = 0.047) and acute graft rejection (OR: 40.73, 95% CI: 3.63-456.98; p = 0.0

252 matological complications and graft failure, graft rejection, or death.

253 f patients with postoperative graft failure, graft rejection, or subsequent surgery at postoperative

254 umulative incidence of complications such as graft rejection (P < 0.001), epitheliopathy (P < 0.001),

255 Graft rejection, patient survival, and non-CMV infection

256 to revise the clinical perspective on acute graft rejection, pending the results of larger studies.

257 rticosteroids may reduce the rate of corneal graft rejection, perhaps especially in the days immediat

258 that subsequent to T cell initiation of skin graft rejection, platelets contribute to further T cell

259 Risk of graft rejection, postoperative complication, and late EC

260 rer immune recovery and in increased risk of graft rejection, pure hematopoietic stem cells (HSC), wh

261 describe the immunosuppressive regimens and graft rejection rates in living-related HLA-identical (L

262 ccessful strategies to induce suppression of graft rejection relies on inhibition of T cell activatio

263 ccessful strategies to induce suppression of graft rejection relies on inhibition of T-cell activatio

264 Endothelial failure and immunological graft rejection remain long-term complications leading t

265 Despite favorable outcomes, immune-mediated graft rejection remains the major cause of corneal allog

266 within allografts, but their contribution to graft rejection remains unclear.

267 ipheral En/DMT correlated significantly with graft rejection severity (r = 0.972, r = 0.729, and r =

268 ted islets maintained euglycemia and delayed graft rejection significantly longer than those receivin

269 fic induction of SENP1 and GATA2 in clinical graft rejection specimens that show endothelial activati

270 al blood mononuclear cells and plasma during graft rejection suggesting potential as a biomarker of g

271 o prime alloreactive T cells and accelerated graft rejection, suggesting that alloimmunity is modulat

272 an MHC class I alloantigen, the accelerated graft rejection T memory response is specifically lost s

273 tic cell (DC) differentiation and suppresses graft rejection, the role of mTORC2 in DCs in determinin

274 istered systemically in mouse models of skin graft rejection, these nanosensors preferentially accumu

275 be the gold standard in diagnosing pancreas graft rejection, they are not performed routinely becaus

276 B cells have been reported to promote graft rejection through alloantibody production.

277 s toward the main effector cells involved in graft rejection through inhibition of natural killer cel

278 ects of PPARgamma agonists on human vascular graft rejection using a model in which human artery is i

279 ze allogeneic entities and that they mediate graft rejection via direct cytotoxicity and priming of a

280 t, but the role of early vascular lesions in graft rejection warrants additional analysis.

281 llow-up was 26 months (range, 12-62 months); graft rejection was 10%.

282 On the other hand, the median time to graft rejection was 28 +/- 5.2 days and 16 +/- 2.6 days

283 mmaRIIb-mediated inhibition of B6.K(d) heart graft rejection was abrogated by increasing T cell help

284 The cause of belatacept-resistant graft rejection was allocated to elevated pretransplant

285 Graft rejection was associated with the development of e

286 Graft rejection was defined as findings of keratic preci

287 o maintain therapeutic levels; no episode of graft rejection was observed during the study.

288 pients; ribavirin did not influence SVR, and graft rejection was rare.

289 Risk factors for development of graft rejection were cessation of postoperative steroid

290 rejection, chronic renal rejection, and skin graft rejection were compared using CD20 or CD19 mAbs.

291 No episodes of immunologic graft rejection were documented.

292 Risk factors for graft rejection were reviewed.

293 (anti-CD3 mAb) and found it could delay skin graft rejection, whereas ipilimumab (anti-CTLA-4 [cytoto

294 perative injuries to an allograft exacerbate graft rejection, which in humans is primarily mediated b

295 on that has been linked to renal and cardiac graft rejection, which was originally thought to be Th1-

296 Selective suppression of graft rejection while maintaining anti-pathogen response

297 In models of vaccination and allogeneic graft rejection, whole body imaging reveals that RA sign

298 Here, we present a case of endothelial graft rejection with an endothelial rejection line occur

299 3D En/DMT maps can diagnose active corneal graft rejection with excellent accuracy, sensitivity, an

300 were at an increased risk for biopsy-proven graft rejection within 4 weeks after detection of CMV re